A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy
文献类型：期刊论文
| 作者 | Shen, Zheyu1,2; Wei, Wei3; Tanaka, Hideyuki2; Kohama, Kazuhiro2; Ma, Guanghui3; Dobashi, Toshiaki4; Maki, Yasuyuki4; Wang, Honghui2; Bi, Jingxiu1; Dai, Sheng1 |
| 刊名 | PHARMACOLOGICAL RESEARCH
 |
| 出版日期 | 2011-10-01 |
| 卷号 | 64期号:4页码:410-419 |
| 关键词 | Galactosamine Drug delivery carrier Targeted therapy Liver cancer |
| ISSN号 | 1043-6618 |
| 通讯作者 | Bi, JX |
| 英文摘要 | In order to minimize the side effect of cancer chemotherapy, a novel galactosamine-mediated drug delivery carrier, galactosamine-conjugated albumin nanoparticles (GAL-AN), was developed for targeted liver cancer therapy. The albumin nanoparticles (AN) and doxorubicin-loaded AN (DOX-AN) were prepared by the desolvation of albumin in the presence of glutaraldehyde crosslinker. Morphological study indicated the spherical structure of these synthesized particles with an average diameter of around 200 nm. The functional ligand of galactosamine (GAL) was introduced onto the surfaces of AN and DOX-AN via carbodiimide chemistry to obtain GAL-AN and GAL-DOX-AN. Cellular uptake and kinetic studies showed that GAL-AN is able to be selectively incorporated into the HepG2 cells rather than AoSMC cells due to the existence of asialoglycoprotein receptors on HepG2 cell surface. The cytotoxicity, measured by MIT test, indicated that AN and GAL-AN are non-toxic and GAL-DOX-AN is more effective in HepG2 cell killing than that of DOX-AN. As such, our results implied that GAL-AN and GAL-DOX-AN have specific interaction with HepG2 cells via the recognition of GAL and asialoglycoprotein receptor, which renders GAL-AN a promising anticancer drug delivery carrier for liver cancer therapy. (C) 2011 Elsevier Ltd. All rights reserved. |
| WOS标题词 | Science & Technology ; Life Sciences & Biomedicine |
| 类目[WOS] | Pharmacology & Pharmacy |
| 研究领域[WOS] | Pharmacology & Pharmacy |
| 关键词[WOS] | CONJUGATED ALBUMIN NANOSPHERES ; MAGNETIC NANOPARTICLES ; POLYMERIC MICELLES ; PROTEIN ; COPOLYMERS ; CELLS |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000295767200022 |
| 公开日期 | 2013-10-30 |
| 版本 | 出版稿 |
| 源URL | [http://ir.ipe.ac.cn/handle/122111/4573]  |
| 专题 | 过程工程研究所_生化工程国家重点实验室 |
| 作者单位 | 1.Univ Adelaide, Sch Chem Engn, Adelaide, SA 5005, Australia 2.Gunma Univ, Grad Sch Med, Dept Mol & Cellular Pharmacol, Gunma 3718511, Japan 3.Chinese Acad Sci, State Key Lab Biochem Engn, Inst Proc Engn, Beijing 100190, Peoples R China 4.Gunma Univ, Fac Engn, Dept Biol & Chem Engn, Gunma 3768515, Japan |
| 推荐引用方式 GB/T 7714 | Shen, Zheyu,Wei, Wei,Tanaka, Hideyuki,et al. A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy[J]. PHARMACOLOGICAL RESEARCH,2011,64(4):410-419. |
| APA | Shen, Zheyu.,Wei, Wei.,Tanaka, Hideyuki.,Kohama, Kazuhiro.,Ma, Guanghui.,...&Dai, Sheng.(2011).A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy.PHARMACOLOGICAL RESEARCH,64(4),410-419. |
| MLA | Shen, Zheyu,et al."A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy".PHARMACOLOGICAL RESEARCH 64.4(2011):410-419. |
入库方式： OAI收割
来源：过程工程研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。